Goto M, Miura T, Itoya M, Sakamoto J, Iimura O
Second Department of Internal Medicine, Sapporo Medical University, School of Medicine.
Basic Res Cardiol. 1993 Nov-Dec;88(6):594-606. doi: 10.1007/BF00788877.
Although previous studies have shown that preconditioning cannot be explained by concurrent myocardial stunning alone, it remains unclear whether reduction of contractile function by preconditioning ischemia is required for its cardioprotective effect. The present study examined whether preconditioning occurs in the absence of regional contractile dysfunction. In the first series of experiments, rabbits received two cycles of 2-min coronary occlusion separated by 5-min reperfusion, with or without dobutamine infusion (10 micrograms/kg/min, i.v.) commencing before the onset of ischemia. Regional thickening fraction measured by epicardial Doppler sensor was 72.8 +/- 4.7% of baseline (mean +/- SEM) in the untreated group and 102.9 +/- 3.1% in the dobutamine group at the end of the second cycle of ischemia/reperfusion. In the second series of the study, four groups of rabbits underwent 30-min coronary occlusion and reperfusion. The control group was untreated, and the PC group was preconditioned with two cycles of 2-min ischemia/5-min reperfusion before the 30-min ischemia. The PC-DOB group received both preconditioning and dobutamine infusion (10 micrograms/kg/min, i.v.), which was started 5 min before the preconditioning and continued for 19 min. The DOB group was given dobutamine infusion like the PC-DOB group, but was not preconditioned. After 72-h reperfusion, infarct size and area at risk were determined by histology and fluorescent particles, respectively. Infarct sizes in the PC and PC-DOB groups (25.0 +/- 3.4% and 22.7 +/- 3.3% of area at risk, respectively) were significantly smaller than that in the control group (48.2 +/- 2.6%). In the DOB groups, infarct size (43.5 +/- 4.0%) was similar to the control value. Infusion of dobutamine at a dose sufficient to abolish the contractile dysfunction which would have been induced by ischemic preconditioning did not attenuate the infarct size-limiting effect of preconditioning. Thus, it is unlikely that reduction of contractile function plays a permissive role in the appearance of the cardioprotective effect of preconditioning.
尽管先前的研究表明,预处理不能仅用同时发生的心肌顿抑来解释,但其缺血预处理导致的收缩功能降低对于其心脏保护作用是否必要仍不清楚。本研究检测了在无局部收缩功能障碍的情况下是否会发生预处理。在第一组实验中,兔子接受两个周期的2分钟冠状动脉闭塞,中间间隔5分钟再灌注,在缺血开始前有或没有静脉输注多巴酚丁胺(10微克/千克/分钟)。在第二个缺血/再灌注周期结束时,未治疗组经心外膜多普勒传感器测量的局部增厚分数为基线的72.8±4.7%(平均值±标准误),多巴酚丁胺组为102.9±3.1%。在第二组研究中,四组兔子接受30分钟冠状动脉闭塞和再灌注。对照组未接受治疗,预处理组在30分钟缺血前用两个周期的2分钟缺血/5分钟再灌注进行预处理。预处理-多巴酚丁胺组接受预处理并静脉输注多巴酚丁胺(10微克/千克/分钟),在预处理前5分钟开始,持续19分钟。多巴酚丁胺组与预处理-多巴酚丁胺组一样接受多巴酚丁胺输注,但未进行预处理。再灌注72小时后,分别通过组织学和荧光颗粒测定梗死面积和危险区域。预处理组和预处理-多巴酚丁胺组的梗死面积(分别为危险区域的25.0±3.4%和22.7±3.3%)显著小于对照组(48.2±2.6%)。在多巴酚丁胺组,梗死面积(43.5±4.0%)与对照值相似。输注足以消除缺血预处理所诱导的收缩功能障碍的剂量的多巴酚丁胺,并未减弱预处理的梗死面积限制效应。因此,收缩功能降低在预处理心脏保护作用的出现中不太可能起允许作用。